Release Date: March 17, 2023 
Expiration Date: March 17, 2024 

Program Overview 
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts. 

Target Audience 
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM. 

Learning Objectives 

• Discuss patient-related and disease-related factors that impact the selection of therapy for patients with relapsed/refractory MM 
• Review the rationale for targeting BCMA in patients with MM, as well as current and emerging approaches that target BCMA, including CAR T-cells, bispecific antibodies, and antibody-drug conjugates  
• Evaluate strategies to manage adverse events that may be encountered with the use of anti-BCMA therapies  

Joint Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bio Ascend LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Physician Continuing Education  
PACE designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Topics of Discussion 

Module 1: Introduction and Rationale for Targeting BCMA on MM Cells
Module 2: BCMA-Targeted CAR T-cells
Module 3: BCMA-Targeted Antibody-Drug Conjugates (ADCs)
Module 4: BCMA-Targeted Bispecifics

Faculty 
Joseph Mikhael, MD, MEd, FRCPC - Moderator
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), 
City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona 

Consultant, Advisor, Speaker: Amgen, BMS, Janssen, Karyopharm, Sanofi, Takeda

Suzanne Lentzsch, MD, PhD  
Professor of Medicine at Columbia University 
Director, Multiple Myeloma and Amyloidosis Service 
Associate Editor, Journal of Clinical Oncology 
Columbia University Medical Center 
New York, New York 

Royalties or Patent Beneficiary: Caelum Bioscience
Consultant, Advisor, Speaker: Takeda, Regeneron, Janssen, GSK, Sanofi, BMS, Adaptive
Consultant, Advisor, Speaker: PeerView, Clinical Care Options (CCO) RedMed
Individual publicly traded stocks and stock options: Magenta, Poseida
Researcher: Zentalis, Sanofi

Krina Patel, MD, MSc  
Associate Professor, Department of Lymphoma/Myeloma 
The University of Texas 
MD Anderson Cancer Center 
Houston, Texas 

Consultant, Advisor, Speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Curio Sciences Bio, Janssen, Legend Biotech, Merck, Oncopeptides, Pfizer, PrecisionBio, Karyopharm 

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Bio Ascend LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer: 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  
 
Instructions for Credit:
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the evaluation 4) complete the post-test with a passing score of 75% or better.

Upon successfully completing the post-test and evaluation, your certifcate will be made available immediately.

Support
This activity is supported by an educational grant from Regeneron.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.